CAMP4 Therapeutics Corporation
Last updated September 27, 2026
Organization details
- Legal name
- CAMP4 Therapeutics Corporation
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Watertown
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CAMP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001736730
Board of directors
-
Amir Nashat · DirectorSince 2024
-
Andrew J. Schwab · DirectorSince 2024
-
Douglas E. Williams · DirectorSince 2025
-
Ingo Chakravarty · DirectorSince 2024
-
James P. Boylan · DirectorSince 2024
-
Josh Mandel-Brehm · Director · Chief Executive OfficerSince 2024
-
Michael F. MacLean · DirectorSince 2026
-
Michael J. Higgins · DirectorSince 2024
-
Murray Stewart · DirectorSince 2025
-
Paula Ragan · DirectorSince 2024
-
Ravi I. Thadhani · DirectorSince 2024
-
Richard A. Young · DirectorSince 2024
-
Steven H. Holtzman · DirectorSince 2024
Chief executives
Josh Mandel-Brehm
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.5%
-
78.5%
Board connections
9 of this board's directors also sit on 14 other boards.
- via Murray Stewart and Paula Ragan
- via Murray Stewart
- via Douglas E. Williams
- via James P. Boylan
- via Andrew J. Schwab
- via James P. Boylan
- via Michael J. Higgins
- via Josh Mandel-Brehm
- via Michael J. Higgins
- via Michael F. MacLean
- via Amir Nashat
- via Andrew J. Schwab
- via Michael J. Higgins
- via James P. Boylan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $99,051
- 5 purchases by 4 insiders
- Sold, last 12 months
- $2,504,037
- 6 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Kelly Gold Officer (Chief Financial Officer) | Open-market purchase | +10,000 | $3.96 | $39,600 |
| Aug 27, 2026 | Andrew J. Schwab Director | Open-market sale | −400,000 | $4.04 | $1,616,000 |
| Aug 24, 2026 | Andrew J. Schwab Director | Open-market sale | −10 | $4.50 | $45 |
| Aug 21, 2026 | Andrew J. Schwab Director | Open-market sale | −32,018 | $4.50 | $144,081 |
| Aug 20, 2026 | Andrew J. Schwab Director | Open-market sale | −114,700 | $4.54 | $520,738 |
| Aug 19, 2026 | Tardiff Daniel Officer (Chief Scientific Officer) | Open-market sale | −1,738 | $4.76 | $8,273 |
| Aug 19, 2026 | Andrew J. Schwab Director | Open-market sale | −45,147 | $4.76 | $214,900 |
| Aug 3, 2026 | Josh Mandel-Brehm Director, Officer (Chief Executive Officer) | Open-market purchase | +6,551 | $1.65 | $10,809 |
| Aug 3, 2026 | Kelly Gold Officer (Chief Financial Officer) | Open-market purchase | +6,551 | $1.65 | $10,809 |
| Aug 3, 2026 | Maricich Yuri Officer (Chief Medical Officer) | Open-market purchase | +6,551 | $1.65 | $10,809 |
| Aug 3, 2026 | Richard A. Young Director | Open-market purchase | +16,378 | $1.65 | $27,024 |
| Sep 11, 2025 | Andrew J. Schwab Director, 10% owner | Grant or award | +2,941,176 | $1.53 | $4,499,999 |
| Sep 11, 2025 | 5AM Ventures VII, L.P. 10% owner | Open-market purchase | +2,941,176 | $1.53 | $4,499,999 |
| Sep 11, 2025 | Polaris Management Co. VII, L.L.C. 10% owner | Open-market purchase | +1,221,721 | $1.53 | $1,869,233 |
| Sep 11, 2025 | Amir Nashat Director, 10% owner | Open-market purchase | +1,221,721 | $1.53 | $1,869,233 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.